Literature DB >> 27048878

Nuclear receptor TLX inhibits TGF-β signaling in glioblastoma.

Erik Johansson1, Qiwei Zhai1, Zhao-Jun Zeng2, Takeshi Yoshida1, Keiko Funa3.   

Abstract

TLX (also called NR2E1) is an orphan nuclear receptor that maintains stemness of neuronal stem cells. TLX is highly expressed in the most malignant form of glioma, glioblastoma multiforme (GBM), and is important for the proliferation and maintenance of the stem/progenitor cells of the tumor. Transforming Growth Factor-β (TGF-β) is a cytokine regulating many different cellular processes such as differentiation, migration, adhesion, cell death and proliferation. TGF-β has an important function in cancer where it can work as either a tumor suppressor or oncogene, depending on the cancer type and stage of tumor development. Since glioblastoma often have dysfunctional TGF-β signaling we wanted to find out if there is any interaction between TLX and TGF-β in glioblastoma cells. We demonstrate that knockdown of TLX enhances the canonical TGF-β signaling response in glioblastoma cell lines. TLX physically interacts with and stabilizes Smurf1, which can ubiquitinate and target TGF-β receptor II for degradation, whereas knockdown of TLX leads to stabilization of TGF-β receptor II, increased nuclear translocation of Smad2/3 and enhanced expression of TGF-β target genes. The interaction between TLX and TGF-β may play an important role in the regulation of proliferation and tumor-initiating properties of glioblastoma cells.
Copyright © 2016. Published by Elsevier Inc.

Entities:  

Keywords:  Smurf1; TGF-β; TGF-β receptor II; TLX; glioblastoma

Mesh:

Substances:

Year:  2016        PMID: 27048878     DOI: 10.1016/j.yexcr.2016.03.028

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  9 in total

1.  Tumorigenic effects of TLX overexpression in HEK 293T cells.

Authors:  Toshima Z Parris; Dzeneta Vizlin-Hodzic; Susanne Salmela; Keiko Funa
Journal:  Cancer Rep (Hoboken)       Date:  2019-07-25

Review 2.  Nuclear receptors in neural stem/progenitor cell homeostasis.

Authors:  Dimitrios Gkikas; Matina Tsampoula; Panagiotis K Politis
Journal:  Cell Mol Life Sci       Date:  2017-06-21       Impact factor: 9.261

3.  uKIN Combines New and Prior Information with Guided Network Propagation to Accurately Identify Disease Genes.

Authors:  Borislav H Hristov; Bernard Chazelle; Mona Singh
Journal:  Cell Syst       Date:  2020-06-24       Impact factor: 10.304

4.  Retinal Degeneration: Short-Term Options and Long-Term Vision for Future Therapy.

Authors:  Shabnam Majidi; Judith M Ogilvie; Colin A Flaveny
Journal:  Mo Med       Date:  2021 Sep-Oct

Review 5.  TLX, an Orphan Nuclear Receptor With Emerging Roles in Physiology and Disease.

Authors:  Adam T Nelson; Yu Wang; Erik R Nelson
Journal:  Endocrinology       Date:  2021-11-01       Impact factor: 5.051

6.  Tracing the origins of glioblastoma by investigating the role of gliogenic and related neurogenic genes/signaling pathways in GBM development: a systematic review.

Authors:  Ovais Shafi; Ghazia Siddiqui
Journal:  World J Surg Oncol       Date:  2022-05-10       Impact factor: 3.253

7.  The protective effects of Zhen-Wu-Tang against cisplatin-induced acute kidney injury in rats.

Authors:  Qi Liu; Shouyu Hu; Yi He; Jiashu Zhang; Xiaona Zeng; Fengtao Gong; Li'na Liang
Journal:  PLoS One       Date:  2017-06-06       Impact factor: 3.240

8.  Orphan nuclear receptor TLX promotes immunosuppression via its transcriptional activation of PD-L1 in glioma.

Authors:  Jiayi Zhou; Xiaojuan Pei; Yingui Yang; Zhu Wang; Weijie Gao; Ran Ye; Xiantong Zhang; Jiangang Liu; Zhuohao Liu; Xinzhi Yang; Jingli Tao; Chunshan Gu; Wei Hu; Franky Lueng Chan; Xin Li; Jie Mao; Dinglan Wu
Journal:  J Immunother Cancer       Date:  2021-04       Impact factor: 13.751

9.  Integrated Analysis of Cell Cycle-Related and Immunity-Related Biomarker Signatures to Improve the Prognosis Prediction of Lung Adenocarcinoma.

Authors:  Fangyu Chen; Jiahang Song; Ziqi Ye; Bing Xu; Hongyan Cheng; Shu Zhang; Xinchen Sun
Journal:  Front Oncol       Date:  2021-06-04       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.